|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Prasugrel#Contraindications]] |
| {{Prasugrel}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Contraindications==
| |
| | |
| ===Active Bleeding===
| |
| | |
| Effient is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
| |
| | |
| ===Prior Transient Ischemic Attack or Stroke===
| |
| | |
| Effient is contraindicated in patients with a history of prior [[transient ischemic attack]] ([[TIA]]) or stroke. In TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on Effient (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic). In patients without such a history, the incidence of stroke was 0.9% (0.2% ICH) and 1.0% (0.3% ICH) with Effient and clopidogrel, respectively. Patients with a history of ischemic stroke within 3 months of screening and patients with a history of [[hemorrhagic stroke]] at any time were excluded from TRITON-TIMI 38. Patients who experience a [[stroke]] or [[TIA]] while on Effient generally should have therapy discontinued [see Adverse Reactions (6.1) and Clinical Studies (14)].
| |
| | |
| ===Hypersensitivity===
| |
| | |
| Effient is contraindicated in patients with [[hypersensitivity]] (e.g., anaphylaxis) to prasugrel or any component of the product [see Adverse Reactions (6.2)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fe9c118-c44b-48d7-a142-9668ae3df0c6 | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fe9c118-c44b-48d7-a142-9668ae3df0c6 | publisher = | date = | accessdate = 6 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antiplatelet drugs]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |